trial · primary record
Lazertinib
Carcinoma, Non-Small-Cell Lung
| Phase | Phase 1 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 701 |
| Primary completion | 2028-03-27 |
| Primary endpoint | Percentage of Participants with Dose-Limiting Toxicity (DLT) (Phase 1) |
| Registry ID | NCT04077463 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:14.403Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04077463
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Lazertinib · compound